Last reviewed · How we verify
MT-8554 low dose
At a glance
| Generic name | MT-8554 low dose |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms (PHASE1)
- A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjects (PHASE1)
- Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy (PHASE2)
- Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy (PHASE2)
- Definitive QT Study With MT-8554 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MT-8554 low dose CI brief — competitive landscape report
- MT-8554 low dose updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI